ESTRO 2024 - Abstract Book

S1334

Clinical - Head & neck

ESTRO 2024

1: Tonneau M, Nebbache R, Larnaudie A, Thureau S, Pointreau Y, Blanchard P, Thariat J. Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy. Cancer Radiother. 2023 Aug 22:S1278-3218(23)00169-5. doi: 10.1016/j.canrad.2023.03.004. Epub ahead of print. PMID: 37620212. 2: Khalladi N, Dejean C, Bosset M, Pointreau Y, Kinj R, Racadot S, Castelli J, Huguet F, Renard S, Guihard S, Tao Y, Rouvier JM, Johnson A, Bourhis J, Xu Shan S, Thariat J. A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients. Cancer Radiother. 2021 Dec;25(8):755-762. doi: 10.1016/j.canrad.2021.04.005. Epub 2021 Sep 23. PMID: 34565664. 3: Sun XS, Michel C, Babin E, De Raucourt D, Péchery A, Gherga E, Géry B, Florescu C, Bourhis J, Thariat J. Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. Future Oncol. 2018 Apr;14(9):877-889. doi: 10.2217/fon-2017-0468. Epub 2018 Mar 26. PMID: 29578359. 4: Penninckx S, Thariat J, Mirjolet C. Radiation therapy-activated nanoparticle and immunotherapy: The next milestone in oncology? Int Rev Cell Mol Biol. 2023;378:157-200. doi: 10.1016/bs.ircmb.2023.03.005. Epub 2023 Apr 21. PMID: 37438017. 5: Van Oirschot M, Bergman A, Verbakel WFAR, Ward L, Gagne I, Huang V, Chng N, Houston P, Symes K, Thomas CG, Basran P, Bowes D, Harrow S, Olson R, Senan S, Warner A, Palma DA, Gaede S. Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):1016-1021. doi: 10.1016/j.ijrobp.2022.01.002. Epub 2022 Jan 12. PMID: 35031340. 6: Mehrens D, Unterrainer M, Corradini S, Niyazi M, Manapov F, Westphalen CB, Froelich MF, Wildgruber M, Seidensticker M, Ricke J, Rübenthaler J, Kunz WG. Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease. Front Oncol. 2021 Jun 15;11:667993. doi: 10.3389/fonc.2021.667993. PMID: 34211842; PMCID: PMC8239286. 7: Qu XM, Chen Y, Zaric GS, Senan S, Olson RA, Harrow S, John-Baptiste A, Gaede S, Mulroy LA, Schellenberg D, Senthi S, Swaminath A, Kopek N, Liu M, Warner A, GB, Palma DA, Louie AV. Is SABR Cost-Effective in OligometastaticCancer? An Economic Analysis of the SABR-COMET Randomized Trial. Int J RadiatOncol Biol Phys. 2021 Apr 1;109(5):1176-1184. doi: 10.1016/j.ijrobp.2020.12.001. Epub 2020 Dec 10. PMID: 33309977. 8: Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38(25):2830 2838. doi: 10.1200/JCO.20.00818

1750

Digital Poster

Hypofractionated radiotherapy for early larynx cancer: 5-year outcomes from a single centre